MedTrace Logo

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

NCT06490328 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2024-07-08

No results posted yet for this study

Summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Conditions

Interventions

DRUG

DKF-MA102

Administered twice at 12-week intervals

Sponsors & Collaborators

  • Dongkook Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Choung-Soo Kim, M.D.,Ph.D · Ewha Womans University Mokdong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2025-05-20
Completion
2025-05-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490328 on ClinicalTrials.gov